2006 considerations for carotid stenting credentialing and
TRANSCRIPT
![Page 1: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/1.jpg)
2006 Considerations for Carotid 2006 Considerations for Carotid
Stenting Credentialing and Practice:Stenting Credentialing and Practice:Training, volume issues, reimbursementTraining, volume issues, reimbursement
Jay S. Yadav MDJay S. Yadav MDCleveland, OHCleveland, OH
![Page 2: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/2.jpg)
YADAVYADAV
Disclosures
◆ Inventor of Angioguard◆ Advisory Board: Cordis, Abbott
![Page 3: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/3.jpg)
YADAVYADAV
![Page 4: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/4.jpg)
YADAVYADAV
High-Risk Patient Trials -High-Risk Patient Trials -Carotid Stenting with Emboli Carotid Stenting with Emboli ProtectionProtection
◆ Randomized against SurgeryRandomized against Surgery◆ SAPPHIRESAPPHIRE
◆ Non-Randomized RegistriesNon-Randomized Registries◆ ARCHERARCHER◆ SHELTER / BEACHSHELTER / BEACH◆ MAVERICKMAVERICK◆ CABERNETCABERNET◆ SECURITYSECURITY
![Page 5: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/5.jpg)
YADAVYADAV
SAPPHIRE STUDYSAPPHIRE STUDYMAEMAE at 360 Days at 360 Days
Rand CEA: 20.1%
Non-Rand Stent: 16.0%
Rand Stent: 12.2%
Non-Randomized Stent Arm vs. Randomized Stent & CEA
Time After Initial Procedure (days)
Cum
ulat
ive
Perc
enta
ge o
f MA
E
Rand CEA: 9.8%
Non-Rand Stent: 6.9%
Rand Stent: 4.8%
Yadav, NEJM, 351: 1493-1501,2004
![Page 6: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/6.jpg)
YADAVYADAV
Cumulative Percentage of Stroke to 30 Days and Cumulative Percentage of Stroke to 30 Days and Ipsilateral Stroke from 31 to 1080 DaysIpsilateral Stroke from 31 to 1080 Days
Days: 0 360 720 1080
CEA: 167 150 (90%) 134 (80%) 112 (67%)
Stent: 167 161 (96%) 154 (92%) 139 (83%)
Randomized Patients
0
510
15
2025
30
35
4045
50
0 90 180 270 360 450 540 630 720 810 900 990 1080Time (days)
Cum
ulat
ive
% o
f Str
oke
CEA Stent LR p=0.945
Stent 7.1%
CEA 3.0%
Stent 4.9% Stent 6.3%CEA 6.7%Stent 3.6% CEA 5.8% CEA 6.7%
30
![Page 7: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/7.jpg)
YADAVYADAV
Cumulative Percentage of Target Lesion Cumulative Percentage of Target Lesion Revascularization at 1080 DaysRevascularization at 1080 Days
Randomized Patients
05
1015
20253035
404550
0 90 180 270 360 450 540 630 720 810 900 990 1080Time (days)
Cu
mu
lati
ve %
of
TL
R
CEA Stent LR p=0.084
CEA 7.1%
Stent 3.0%
Days: 0 360 720 1080
CEA: 167 150 (90%) 134 (80%) 112 (67%)
Stent: 167 161 (96%) 154 (92%) 139 (83%)
![Page 8: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/8.jpg)
YADAVYADAV
4.72.9
1.1 0.7
3.4
0.8 0.50
2.0
0.10
5
10
15
All Stroke Major Ipsi Major Non-Ipsi Minor Ipsi Minor Non-Ipsi
Symptomatic (n=274)Asymptomatic (n=974)
%
Stroke at 30-Days Symptomatic vs. Asymptomatic
CASES -PMS
Adjudicated data
![Page 9: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/9.jpg)
YADAVYADAV
SapphireSapphire BeachBeachArcherArcher SecuritySecurityMavericMaveric CabernetCabernet
World RegistryWorld RegistryCarotid StentingCarotid Stenting
2,400 patients2,400 patients
11,035 patients11,035 patients
16,070 patients16,070 patients
How much more data do we need?!?!How much more data do we need?!?!
German Carotid RegistryGerman Carotid Registry 2,427 patients2,427 patients
High Risk Trials/Registries:High Risk Trials/Registries:
![Page 10: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/10.jpg)
Low to Moderate Risk Low to Moderate Risk PatientsPatients
![Page 11: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/11.jpg)
YADAVYADAV
Moderate Risk Patients – Moderate Risk Patients – CREST Lead InCREST Lead In
30 day Stroke/Death30 day Stroke/Death
◆ 527 Pts527 Pts 3.4%3.4%◆ AsxAsx 2.4%2.4% <ACAS <ACAS ◆ SxSx 5.6%5.6% <NASCET<NASCET◆ < 60 yrs: < 60 yrs: 2% 2%
◆ Lenox Hill 187 ptsLenox Hill 187 pts 1.6% 1.6%
Hobson, AHA 2003Hobson, AHA 2003
![Page 12: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/12.jpg)
YADAVYADAV
CARESS Lead In – Low CARESS Lead In – Low RiskRisk
30 Day Events30 Day EventsCEACEA StentStent
Stroke/DeathStroke/Death 2%2% 2%2%Stroke/Death/MIStroke/Death/MI 3%3% 2%2%
![Page 13: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/13.jpg)
YADAVYADAV
Who Should Treat Patients Who Should Treat Patients with Carotid Disease ?with Carotid Disease ?
◆ CardiologistsCardiologists◆ RadiologistsRadiologists◆ SurgeonsSurgeons◆ NeurologistsNeurologists◆ Vascular InternistsVascular Internists
![Page 14: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/14.jpg)
YADAVYADAV
COCATSCOCATSACC March 2002
![Page 15: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/15.jpg)
YADAVYADAV
Worldwide RegistryWorldwide Registry
6 3 %
2 5 %
1 2 %0%
25%
50%
75%
C A R D I O L O G Y R A D I O L O G Y S U R G E R Y
Carotid Stent by Physician SpecialtyCarotid Stent by Physician Specialty
Wholey and Wholey; Cath and Cardiovascular Intervent;1998.Wholey and Wholey; Cath and Cardiovascular Intervent;1998.
![Page 16: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/16.jpg)
YADAVYADAV
Credentials = PrivilegesCredentials = Privileges
◆ Local hospital function.Local hospital function.◆ Rules apply equally to all Rules apply equally to all
specialties.specialties.◆ Quality assurance function.Quality assurance function.
![Page 17: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/17.jpg)
YADAVYADAV
Certification = GuidelinesCertification = Guidelines
◆ Professional societies or associations.Professional societies or associations.◆ Payers.Payers.◆ Government agencies.Government agencies.
![Page 18: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/18.jpg)
YADAVYADAV
CERTIFYING CERTIFYING ORGANIZATIONSORGANIZATIONS
◆ ACC/AHAACC/AHA◆ SCAI SCAI (Society of Cardiac Angiography and Intervention).(Society of Cardiac Angiography and Intervention).
◆ ISCI ISCI (International Society of Cardiovascular (International Society of Cardiovascular Interventionists).Interventionists).
◆ SIR SIR (Society of Interventional Radiologists).(Society of Interventional Radiologists).
◆ SVS SVS (Society of Vascular Surgery).(Society of Vascular Surgery).
![Page 19: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/19.jpg)
YADAVYADAV
Cognitive: Cognitive: The fund of knowledge for vascular disease, natural history, The fund of knowledge for vascular disease, natural history,
pathophysiology, diagnostic methods, and treatment pathophysiology, diagnostic methods, and treatment
alternatives. alternatives.
Technical:Technical: Competence in both diagnostic angiography and Competence in both diagnostic angiography and
interventional techniques.interventional techniques.
Clinical:Clinical: The ability to manage inpatients, interpret diagnostic tests, The ability to manage inpatients, interpret diagnostic tests,
obtain consent, admittingobtain consent, admitting privileges, assessment of risk to privileges, assessment of risk to
benefit ratio.benefit ratio.
REQUIRED SKILL ELEMENTSREQUIRED SKILL ELEMENTSENDOVASCULAR COMPETENCEENDOVASCULAR COMPETENCE
![Page 20: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/20.jpg)
YADAVYADAV
200 cerebral angiograms 5 carotid stents
![Page 21: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/21.jpg)
YADAVYADAV
Background of Interventional Experience30 cerebral angiograms - half as primary operator25 carotid stents - half as primary operator
![Page 22: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/22.jpg)
YADAVYADAV
AHA/ACC GUIDELINES FOR PTAAHA/ACC GUIDELINES FOR PTA(1993)(1993)
◆ AHA/ACC CRITERIA.AHA/ACC CRITERIA.◆ 100 diagnostic angiograms with 50 as 1º 100 diagnostic angiograms with 50 as 1º
operator.operator.◆ 50 PTA’s with 25 as 1º operator.50 PTA’s with 25 as 1º operator.◆ No distribution requirements.No distribution requirements.◆ No threshold event rate.No threshold event rate.◆ Not specialty specific.Not specialty specific.◆ Completely arbitrary criteria.Completely arbitrary criteria.
![Page 23: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/23.jpg)
YADAVYADAV
Ideal Cardiology Carotid CriteriaIdeal Cardiology Carotid Criteria
◆ Experienced interventional cardiologist (≥ 200 coronary interventions).Experienced interventional cardiologist (≥ 200 coronary interventions).◆ Skilled with SVG-EPD’s (≥ 20 cases).Skilled with SVG-EPD’s (≥ 20 cases).◆ Credentialed to perform non-coronary angiography and angioplasty.Credentialed to perform non-coronary angiography and angioplasty.◆ Committed to carotid “fund of knowledge”.Committed to carotid “fund of knowledge”.
◆ Neurology/Vascular medicine/surgeon partner.Neurology/Vascular medicine/surgeon partner.◆ Attendance at live demonstration course.Attendance at live demonstration course.
◆ Carotid angiograms ≥ 50 proctored cases with stroke and death rate ≤ 1%.Carotid angiograms ≥ 50 proctored cases with stroke and death rate ≤ 1%.◆ 1 month, 6 month, 12 month, and with annual review.1 month, 6 month, 12 month, and with annual review.◆ Proctoring/case review for threshold rate achieved.Proctoring/case review for threshold rate achieved.
◆ Carotid stents with EPD ≥ 25 proctored cases with stroke and death rate ≤ 5%.Carotid stents with EPD ≥ 25 proctored cases with stroke and death rate ≤ 5%.◆ 1 month, 6 month, 12 month, and with annual review.1 month, 6 month, 12 month, and with annual review.◆ Proctoring/case review for threshold rate achieved.Proctoring/case review for threshold rate achieved.
![Page 24: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/24.jpg)
YADAVYADAV
Ranges of simulationsRanges of simulations
Manikin-based simulations use a plastic manikin with sophisticated software, dedicated workstations and realistic tactile feedback.
These $10MM flight simulators are used to train airline pilots from around the world and they exactly replicate the flight deck of the real aircraft, with sophisticated views of the outside world.
Visual Simulations
Visual Simulations allow users to interact with virtual representations of types of input/output criteria, with multiple branches.
![Page 25: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/25.jpg)
YADAVYADAV
EducationEducation
◆ Cardiologists and SurgeonsCardiologists and Surgeons◆ Active Training ProgramActive Training Program◆ FDA will Mandate Training FDA will Mandate Training ◆ Medical SimulationMedical Simulation
◆ Simbionix, Mentice, SimSuiteSimbionix, Mentice, SimSuite◆ Vascular and CoronaryVascular and Coronary◆ Fellow EducationFellow Education
![Page 26: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/26.jpg)
YADAVYADAV
CAPTURE: Primary Safety Events by CAPTURE: Primary Safety Events by Physician Experience Level Physician Experience Level
CAPTURE (N=1603)
HighN=166
MediumN=1177
LowN=260
Deatha. 0.0% 1.6% 2.3%
Strokea.
Major Minor
5.4%1.2%4.2%
3.7%1.7%2.0%
4.6%2.7%1.9%
MIa. 0.6% 0.8% 1.2%S/D/MIb 6.0% 4.8% 5.8%
S/Db 5.4% 4.3% 5.0%
a.Non-hierarchicalbHierarchical
![Page 27: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/27.jpg)
YADAVYADAV
3.04.1
0.4
4.35.8
3.74.5
0.8 0.61.9
0 0.70
5
10
15Operator Volume High: >75 CAS/year (n=640)
Operator Volume Medium: 25-75 CAS/year (n=468)
Operator Volume Low: <25 CAS/year (n=134)
%
Major Adverse Events at 30-Days
Death MI MAEStroke
Operator Volume
CASES -PMS
Adjudicated data
![Page 28: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/28.jpg)
YADAVYADAV
FDA FDA
◆ SAPPHIRE high risk criteriaSAPPHIRE high risk criteria◆ Symptomatic 50% stenosisSymptomatic 50% stenosis◆ Asymptomatic 80% stenosisAsymptomatic 80% stenosis
![Page 29: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/29.jpg)
YADAVYADAV
CMSCMS
◆ SAPPHIRE High RiskSAPPHIRE High Risk◆ Symptomatic 70%Symptomatic 70%
![Page 30: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/30.jpg)
YADAVYADAV
7.5%6.5%
5.5%
0.0%0%
2%
4%
6%
8%
10%
12%
14%
SAPPHIRE SYMPRand
SAPPHIRE SYMPNon-Rand
NASCET ECST
30-Day Ipsilateral Stroke
STENTING vs OTHER SURGICAL TRIALSSTENTING vs OTHER SURGICAL TRIALSSymptomatic Symptomatic PatientsPatients
Error Bar = 95% CIError Bar = 95% CI
%
![Page 31: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/31.jpg)
YADAVYADAV
2.5%1.8%
3.2%4.3%
0%
2%
4%
6%
8%
10%
SAPPHIRE ASYMPRand
SAPPHIRE ASYMPNon-Rand
ACAS ACST
30-Day Ipsilateral Stroke
STENTING vs OTHER SURGICAL TRIALSSTENTING vs OTHER SURGICAL TRIALSAsymptomaticAsymptomatic Patients Patients
Error Bar = 95% CIError Bar = 95% CI
%
![Page 32: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/32.jpg)
YADAVYADAV
30-Day Risk of Stroke in 30-Day Risk of Stroke in High Risk Carotid Stenting TrialsHigh Risk Carotid Stenting Trials
0
2
4
6
8
10
12
14
Patie
nts
(%)
Patie
nts
(%)
3.1%
ARCHeRARCHeR 22SAPPHIRE
Rand Non-RandSECuRITYSECuRITYBEACHBEACH
4.9%5.8%
3.3%Ipsil
4.2% 3.2%DeviceOnly
6.2%
MavericMaveric 22
CabernetCabernet
![Page 33: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/33.jpg)
YADAVYADAV
-$10,000
-$5,000
$0
$5,000
$10,000
-0.5 -0.25 0 0.25 0.5
∆ Quality-Adjusted Life Expectancy (yrs)
LIFETIME Cost and QALYs
$50,000/QALY
Base Case∆ Cost = $3515
∆ Life Exp = 0.179 QALYsC/E ratio = $19,652/QALY
![Page 34: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/34.jpg)
YADAVYADAV
CMS PositionCMS Position
◆ CEA Reimbursed:CEA Reimbursed:◆ Any PatientAny Patient◆ Sx > 50%Sx > 50%◆ Asx > 60%Asx > 60%
◆ CAS Reimbursed:CAS Reimbursed:◆ Sx > 70% High RiskSx > 70% High Risk
![Page 35: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/35.jpg)
YADAVYADAV
CMS PositionCMS Position
More Invasive Procedure (CEA)More Invasive Procedure (CEA)
Less InvasiveProcedure
(CAS)
CAROTIDCAROTID
DISEASEDISEASE
![Page 36: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/36.jpg)
YADAVYADAV
CLINICAL CLINICAL CONSEQUENCE?CONSEQUENCE?
◆ Medicare patients will continue to get Medicare patients will continue to get CEA when they could benefit from a CEA when they could benefit from a less invasiveless invasive treatment which is treatment which is at at leastleast as safe as CEA. as safe as CEA.
![Page 37: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/37.jpg)
YADAVYADAV
More Data?More Data?
◆ Low Risk Asymptomatic and Low Risk Asymptomatic and Moderate Stenosis Symptomatic Trials Moderate Stenosis Symptomatic Trials BUT they are randomized to CEA BUT they are randomized to CEA
◆ CMS is taking the position that CEA is CMS is taking the position that CEA is not Proven in these Patientsnot Proven in these Patients
![Page 38: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/38.jpg)
YADAVYADAV
What Can You Do?What Can You Do?
◆ Express your opinionExpress your opinion◆ [email protected]@cms.hhs.gov
◆ Medical Societies need to speak with Medical Societies need to speak with one voiceone voice
◆ Educate Your Patients, Congressional Educate Your Patients, Congressional RepresentativesRepresentatives
![Page 39: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/39.jpg)
YADAVYADAV
CONCLUSIONS:CONCLUSIONS:High Risk PatientsHigh Risk Patients
◆ Protected Carotid Stenting is Protected Carotid Stenting is Superior to CEA in Pts with Co-Superior to CEA in Pts with Co-Morbid ConditionsMorbid Conditions
◆ Protected Stenting: Lower risk of Protected Stenting: Lower risk of Major Ipsilateral Stroke, MI, CN Major Ipsilateral Stroke, MI, CN Injury and RevascularizationInjury and Revascularization
![Page 40: 2006 Considerations for Carotid Stenting Credentialing and](https://reader035.vdocuments.site/reader035/viewer/2022072417/62dc8f18ccbfdb6632120d01/html5/thumbnails/40.jpg)
YADAVYADAV
ConclusionsConclusions
◆ Credentialing Criteria Have Been Credentialing Criteria Have Been DevelopedDeveloped
◆ Training Programs – Industry Training Programs – Industry Sponsored, FDA MandatedSponsored, FDA Mandated